TransCode Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- TransCode Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- RNAZ
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001829635
Board of directors
-
Erik Manting · DirectorSince 2023
-
Magda Marquet · DirectorSince 2023
-
Philippe Calais · DirectorSince 2023
-
Robert Michael Dudley · Director · Chief Executive OfficerSince 2023
-
Thomas A. Fitzgerald · Director · Interim CEO, CFOSince 2023
Chief executives
Robert Michael Dudley
· Chief Executive Officer
Dates unknown
Dates unknown
Board connections
1 of this board's directors also sit on 3 other boards.
- via Magda Marquet
- via Magda Marquet
- via Magda Marquet
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 28, 2023 | Thomas A. Fitzgerald Director, Officer (Chief Financial Officer) | Open-market purchase | +49,350 | $0.51 | $25,169 |
| Sep 28, 2023 | Robert Michael Dudley Director, Officer (Chief Executive Officer) | Open-market purchase | +98,000 | $0.51 | $49,980 |
| Jun 21, 2023 | Robert Michael Dudley Director, Officer (Chief Executive Officer) | Open-market purchase | +12,000 | $2.65 | $31,800 |
| Jun 20, 2023 | Robert Michael Dudley Director, Officer (Chief Executive Officer) | Open-market purchase | +6,607 | $2.55 | $16,848 |
| Jun 9, 2023 | Robert Michael Dudley Director, Officer (Chief Executive Officer) | Open-market purchase | +19,000 | $2.76 | $52,440 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.